A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
A phase 2 trial of Disitamab vedotin and Tucatinib in gastric & gastro-oesophageal junction cancer, HER2-positive breast cancer and triple-negative breast cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
Overview
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors is a phase 2 interventional study registered as NCT06157892 by Seagen, a wholly owned subsidiary of Pfizer, with 54 participants enrolled, started 2024-05-20 and due to reach its primary completion in 2029-07-28. Interventions recorded: disitamab vedotin and tucatinib.
Similar pages
not linked directly; found by shared links- TrialDV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialDV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer and the tag pipeline.
- TrialTo Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Shares RemeGen, Disitamab vedotin and the tag pipeline.
- TrialEfficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer and the tag pipeline.
- TrialPerioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialNeoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer and the tag pipeline.
- TrialTo Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer and the tag pipeline.